Skip to main content
Erschienen in:
Buchtitelbild

2017 | OriginalPaper | Buchkapitel

1. Introduction

verfasst von : Naitee Ting, Ding-Geng Chen, Shuyen Ho, Joseph C. Cappelleri

Erschienen in: Phase II Clinical Development of New Drugs

Verlag: Springer Singapore

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config
loading …

Abstract

Most of the drugs available in pharmacy started out as a chemical compound or a biologic discovered in laboratories.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 340 Zeitschriften

aus folgenden Fachgebieten:

  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Versicherung + Risiko




Jetzt Wissensvorsprung sichern!

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 390 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Maschinenbau + Werkstoffe




 

Jetzt Wissensvorsprung sichern!

Literatur
Zurück zum Zitat Cappelleri, J. C., & Spielberg, S. P. (2015). Advances in clinical outcome assessments. Therapeutic Innovation & Regulatory Science, 49, 780–782.CrossRef Cappelleri, J. C., & Spielberg, S. P. (2015). Advances in clinical outcome assessments. Therapeutic Innovation & Regulatory Science, 49, 780–782.CrossRef
Zurück zum Zitat Cappelleri, J. C., Zou, K. H., Bushmakin, A. G., Alvir, J. M. J., Alemayehu, D., & Symonds, T. (2013). Patient-reported outcomes: Measurement, implementation and interpretation. Boca Raton, Florida: Chapman & Hall/CRC Press. Cappelleri, J. C., Zou, K. H., Bushmakin, A. G., Alvir, J. M. J., Alemayehu, D., & Symonds, T. (2013). Patient-reported outcomes: Measurement, implementation and interpretation. Boca Raton, Florida: Chapman & Hall/CRC Press.
Zurück zum Zitat Chow, S. C., & Liu, J. P. (1999). Design and analysis of bioavailability and bioequivalence studies. New York: Marcel Dekker, Inc.MATH Chow, S. C., & Liu, J. P. (1999). Design and analysis of bioavailability and bioequivalence studies. New York: Marcel Dekker, Inc.MATH
Zurück zum Zitat Crowley, J., & Hoering, A. (2012). Handbook of statistics in clinical oncology (3rd ed.). Boca Raton, FL: Chapman & Hall/CRC Press. Crowley, J., & Hoering, A. (2012). Handbook of statistics in clinical oncology (3rd ed.). Boca Raton, FL: Chapman & Hall/CRC Press.
Zurück zum Zitat Doward, L.C., Gnanasakthy, A., & Baker, M.G. (2010). Patient reported outcomes: Looking beyond the claim. Health and Quality of Life Outcomes, 8, 89 (Open access). Doward, L.C., Gnanasakthy, A., & Baker, M.G. (2010). Patient reported outcomes: Looking beyond the claim. Health and Quality of Life Outcomes, 8, 89 (Open access).
Zurück zum Zitat Drummon, M. F., Sculpher, M. J., Torrance, G. W., O’Brien, B. J., & Stoddart, G. (2005). Methods for the economic evaluation of health care programmes (3rd ed.). New York, NY: Oxford University Press. Drummon, M. F., Sculpher, M. J., Torrance, G. W., O’Brien, B. J., & Stoddart, G. (2005). Methods for the economic evaluation of health care programmes (3rd ed.). New York, NY: Oxford University Press.
Zurück zum Zitat Fairclough, D. L. (2004). Patient reported outcomes as endpoints in medical research. Statistical Methods in Medical Research, 13, 115–138.CrossRefMATHMathSciNet Fairclough, D. L. (2004). Patient reported outcomes as endpoints in medical research. Statistical Methods in Medical Research, 13, 115–138.CrossRefMATHMathSciNet
Zurück zum Zitat Fairclough, D. L. (2010). Design and analysis of quality of life studies in clinical trials (2nd ed.). Boca Raton, Florida: Chapman & Hall/CRC.MATH Fairclough, D. L. (2010). Design and analysis of quality of life studies in clinical trials (2nd ed.). Boca Raton, Florida: Chapman & Hall/CRC.MATH
Zurück zum Zitat Finney, D. J. (1978). Statistical methods in biological assay (3rd ed.). London: Charles Griffin.MATH Finney, D. J. (1978). Statistical methods in biological assay (3rd ed.). London: Charles Griffin.MATH
Zurück zum Zitat Glick, H. A., Doshi, J. A., Sonnad, S. S., & Polsky, D. (2005). Economic evaluation in clinical trials (2nd ed.). New York, NY: Oxford University Press. Glick, H. A., Doshi, J. A., Sonnad, S. S., & Polsky, D. (2005). Economic evaluation in clinical trials (2nd ed.). New York, NY: Oxford University Press.
Zurück zum Zitat Green, S., & Benedetti, J. (2012). Clinical trials in oncology (3rd ed.). Boca Raton, FL: Chapman & Hall/CRC Press. Green, S., & Benedetti, J. (2012). Clinical trials in oncology (3rd ed.). Boca Raton, FL: Chapman & Hall/CRC Press.
Zurück zum Zitat ICH-E4. (1994). Harmonized tripartite guideline dose-response information to support drug registration. ICH-E4. (1994). Harmonized tripartite guideline dose-response information to support drug registration.
Zurück zum Zitat Morrow, T. (2004). Defining the difference: What makes biologics unique. Biotechnology Healthcare, 24–29. Morrow, T. (2004). Defining the difference: What makes biologics unique. Biotechnology Healthcare, 24–29.
Zurück zum Zitat Muenning, P. (2007). Cost-effectiveness analysis in health: A practical approach (2nd ed.). San Francisco, California: Jossey-Bass. Muenning, P. (2007). Cost-effectiveness analysis in health: A practical approach (2nd ed.). San Francisco, California: Jossey-Bass.
Zurück zum Zitat Selwyn, M.R. (1988). Preclinical safety assessment. In K.E. Peace (Ed.), Biopharmaceutical statistics for drug development. New York: Marcel Dekker, Inc. Selwyn, M.R. (1988). Preclinical safety assessment. In K.E. Peace (Ed.), Biopharmaceutical statistics for drug development. New York: Marcel Dekker, Inc.
Zurück zum Zitat Ting, N. (2003). Drug development, encyclopedia of biopharmaceutical statistics (2nd ed., pp. 317–324). Marcel Dekker. Ting, N. (2003). Drug development, encyclopedia of biopharmaceutical statistics (2nd ed., pp. 317–324). Marcel Dekker.
Zurück zum Zitat Ting, N. (2006). Introduction and drug development process, dose finding in drug development (pp. 1–17). New York: Springer. Ting, N. (2006). Introduction and drug development process, dose finding in drug development (pp. 1–17). New York: Springer.
Metadaten
Titel
Introduction
verfasst von
Naitee Ting
Ding-Geng Chen
Shuyen Ho
Joseph C. Cappelleri
Copyright-Jahr
2017
Verlag
Springer Singapore
DOI
https://doi.org/10.1007/978-981-10-4194-5_1